**High-Level Overview (2–3 sentences)**  
The speaker explains how parents and caregivers can understand, evaluate, and responsibly participate in clinical trials for Angelman syndrome, focusing on the family’s perspective rather than the sponsor’s or regulator’s. She walks through what clinical trials are, how to find and enroll in them, what informed consent really means, what parents must commit to, and how to behave ethically to protect both their child and the integrity of the research.

---

## Speaker Introduction

- The speaker is a scientist and parent advocate deeply involved in Angelman syndrome research and clinical development.  
- She is the Chief Scientific Officer (CSO) of FAST (Foundation for Angelman Syndrome Therapeutics), co-director of the ABOM (Angelman Biomarker and Outcome Measure) program, and associated with AS2 Bio.  
- Most importantly for this talk, she speaks as a mother of a child with Angelman syndrome (her son Quincy), explicitly “wearing her parent hat” to focus on what families need to know and ask.

---

## Main Sections / Topics (in order)

1. What a clinical trial is and why it matters for families  
2. Inclusion and exclusion criteria: who can and cannot participate  
3. Phases of clinical trials and current Angelman programs  
4. Steps to enrollment: from finding a trial to baseline assessments  
5. Informed consent: what it is and how to use it wisely  
6. Participation, follow-up, and safety reporting  
7. Key questions parents should ask before enrolling  
8. Practical checklist and logistics for families  
9. Clinical trial etiquette and confidentiality  
10. Empowerment, documentation, and closing advice  

---

### 1. What a clinical trial is and why it matters for families

Clinical trials are structured research studies that test new drugs, devices, or therapies in people to evaluate safety and potential effectiveness. For newly diagnosed families, it’s crucial to understand that trials are not routine treatment; they are experiments with both potential benefit and real, unknown risks. Trials are conducted under strict regulatory oversight, which means there are rules about how the study is run and what participants must do. Parents are true partners in this process: their commitment to showing up, following the protocol, and reporting accurately is essential to discovering whether a therapy works. Enrolling a child in a trial is a serious, voluntary decision that requires weighing hope against uncertainty and risk.

---

### 2. Inclusion and exclusion criteria: who can and cannot participate

Every clinical trial has **inclusion criteria** (what a person must have to be eligible) and **exclusion criteria** (what disqualifies someone from that specific trial). These criteria can include age, genotype (e.g., deletion, mutation, UPD, ICD), prior treatments, other medical conditions (heart, kidney disease, etc.), current medications, and functional abilities (like being ambulatory). These rules are not about rejecting families but about safety and scientific clarity—some combinations of conditions or treatments could make participation unsafe or make the data impossible to interpret. Being excluded from one trial does not mean being excluded from all trials; criteria can change as more is learned about a therapy. Parents must be honest about their child’s abilities and health (for example, how much they truly walk) because misrepresenting this can put the child at risk.

---

### 3. Phases of clinical trials and current Angelman programs

Before human trials, there is a **“phase 0”** or preclinical stage: animal studies and lab work to justify first-in-human testing. Early human trials in rare disease often combine **Phase 1/2**, using very small numbers of participants (sometimes 6–12 in gene therapy) to study safety, dosing, and early signs of effect and durability. **Phase 3** (pivotal) trials involve more participants and often include a control group (placebo or no treatment) to compare outcomes, though some interventions (like invasive gene therapy) cannot ethically use a true placebo surgery. In Angelman syndrome, there are multiple active programs at different stages: AAV gene therapy, antisense oligonucleotides (ASOs) now in Phase 3, HSC gene therapy, CRISPR gene editing, small molecules, and downstream-target drugs (e.g., from Roche, Neuren). Each program has a different risk profile and design, so trials will look different and include different types of patients.

---

### 4. Steps to enrollment: from finding a trial to baseline assessments

Enrolling in a trial is a multi-step process: find the trial, pre-screen, screen, sign informed consent, enroll, complete baseline assessments, then receive study treatment and follow-up. The main public tool to **find** trials is [clinicaltrials.gov](https://www.clinicaltrials.gov): search “Angelman syndrome” to see open, recruiting, or planned studies, sites, and contact information. Advocacy groups like FAST and ASF also share trial announcements via websites, newsletters, and social media, but families must still do their own regular checking. Once interested, families should discuss suitability with their neurologist or care team, then contact the trial site or sponsor to start **pre-screening**. If pre-screening suggests eligibility, a **screening visit** at the site will confirm details, collect initial health data, and plan baseline assessments (e.g., blood work, MRI, lumbar puncture if needed).

---

### 5. Informed consent: what it is and how to use it wisely

The **informed consent form (ICF)** is a legal and ethical document that must be signed before any study procedures (blood draws, MRIs, etc.) can be done. It explains the trial’s goals, procedures, schedule, duration, risks, potential benefits, privacy protections, and your right to withdraw. Many parents are so excited they sign without reading, but this is dangerous: early-stage trials carry real, sometimes unknown risks, and you are authorizing those risks for your child. Parents have the right to ask detailed questions: dose, site experience with the procedure, experience with the technology in humans and animals, and any prior Angelman-specific data. Families should read the ICF carefully (even on the plane or in the car), write down questions in advance, and only sign once they truly understand what they are agreeing to.

---

### 6. Participation, follow-up, and safety reporting

Once enrolled, the child receives a de-identified study ID and undergoes **baseline assessments** (e.g., ORCA, Bayley, Vineland, MRI/CT) to establish a starting point. Over time, these assessments are repeated to see changes; some are **clinician-reported** (tests done by professionals) and others are **parent-reported** (questionnaires, interviews, tablet-based surveys). Parents must attend scheduled visits, follow instructions, and report **all** side effects or changes, whether they think they are drug-related or not. The study doctor decides if an event is likely related to the drug, but parents have the right and responsibility to say, “This started after treatment; I believe it may be related.” Follow-up can last months to many years (5–15 years for gene therapy), so families must understand the long-term commitment and keep engaging with study updates (press releases, conference presentations, investor calls) where aggregate results are shared.

---

### 7. Key questions parents should ask before enrolling

Parents should ask: **What is the goal of this trial?** and **What are the possible risks and benefits?** They should clarify what happened in animal studies and what that might mean for humans, including any known safety concerns. It’s critical to know whether the child will receive active treatment, placebo, sham procedure, or sugar pill, and if on control, whether and when they can cross over to active treatment. Families must understand the visit schedule: how often they must travel, what can be done locally, and how many EEGs, blood draws, MRIs, lumbar punctures, etc. are required. They should also ask who pays for travel, lodging, food, parking, and whether there is an open-label extension or continued access to the drug after the trial ends.

---

### 8. Practical checklist and logistics for families

Families should create a **checklist**: read and understand the ICF, ask all questions, and keep copies of all documents. They need to know exactly who their contact person is (name, phone, email) and feel free to reach out with any concerns. Keeping a clear schedule of all appointments and travel plans is essential; if you know you cannot reliably meet the schedule, you should not enroll, as this wastes a slot and can harm the study. Parents should discuss travel, lodging, and reimbursement logistics in advance so there are no surprises. Always remember the right to withdraw at any time if you become uncomfortable, while still cooperating with any recommended safety follow-up.

---

### 9. Clinical trial etiquette and confidentiality

Parents are strongly urged **not** to share trial details publicly on social media (Facebook, Instagram, TikTok, LinkedIn, “private” groups, etc.). Public sharing can create unrealistic expectations, bias perceptions, and even damage the scientific integrity of the trial, especially when early phases are open-label and people start predicting what “should” happen. The same primary caregiver should complete all parent-reported assessments throughout the trial to maintain consistency (if dad starts, dad should continue; if mom starts, mom should continue). Families should avoid discussing their specific trial experiences with other community members at sites or conferences, and should not approach industry representatives (e.g., Ionis, Ultragenyx, Roche) to describe their child’s experience, because sponsors are meant to remain blinded. Respecting confidentiality, data integrity, and your child’s privacy is part of being a responsible research partner.

---

### 10. Empowerment, documentation, and closing advice

Parents should report all adverse events—drug-related or not—to the trial site so that future families can understand real risks; hiding problems can endanger others. To track their own child’s journey, families are encouraged to **document skills with videos** before and after treatment (what the child could and could not do), even if the study itself doesn’t request those videos. Listening to study updates and sharing honest experiences (good or bad) with the study doctor—not on social media—helps improve care and research. Empowerment comes from knowledge: understanding options, asking questions, and making informed decisions rather than reacting out of fear or excitement. The speaker closes by emphasizing that “knowledge is power,” and that families, by engaging thoughtfully and responsibly, are central to advancing treatments for Angelman syndrome.